Products for Research Use Only

JANEX-1

CAT: 0804-HY-15508-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-15508-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
JANEX-1 (WHI-P131) is a potent and specific JAK3 inhibitor (estimated Ki=2.3 μM) . JANEX-1 (WHI-P131) shows potent JAK3-inhibitory activity (IC50 of 78 μM), does not inhibit JAK1 and JAK2.
CAS Number
202475-60-3
Product Name Alternative
WHI-P131; Jak3 inhibitor I
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
JAK
Type
Reference compound
Related Pathways
Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/JANEX-1.html
Concentration
10mM
Purity
99.63
Solubility
DMSO : ≥ 100 mg/mL
Smiles
OC1=CC=C(NC2=C3C=C(OC)C(OC)=CC3=NC=N2)C=C1
Molecular Formula
C16H15N3O3
Molecular Weight
297.31
Precautions
H302, H315, H319, H335
References & Citations
[1]Sudbeck EA, et al. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Clin Cancer Res. 1999 Jun;5 (6) :1569-82.|[2]Oh YB, et al. Inhibition of Janus activated kinase-3 protects against myocardial ischemia and reperfusion injury in mice. Exp Mol Med. 2013 May 17;45:e23|[3]Uckun FM, et al. In vivo toxicity and pharmacokinetic features of the janus kinase 3 inhibitor WHI-P131 [4- (4'hydroxyphenyl) -amino-6,7- dimethoxyquinazoline. Clin Cancer Res. 1999 Oct;5 (10) :2954-62.|[4]Xia F, et al. IL4 (interleukin 4) induces autophagy in B cells leading to exacerbated asthma. Autophagy. 2018;14 (3) :450-464.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
JAK3